India's Sun Pharmaceutical Industries Ltd (SUN.BO) said on Tuesday it had received approval from the U.S. Food and Drug Administration to launch generic version of AstraZeneca Plc's (AZN.L) prostate cancer drug Casodex.

The Indian drug maker said in a statement that AstraZeneca (AZN.L) had annual sales of Casodex of $314 million in the United States.

Ahead of the announcement, shares in Sun Pharma rose 1.2 percent to 1,143.35 rupees in the main Mumbai market .BSESN that ended 0.9 percent higher.

---

Add this page to your favorite Social Bookmarking websites